Key Points:
·Milestone Achievement: Cytisinicline becomes the first non-nicotine smoking cessation drug to be submitted for FDA approval in 20 years.
·International Recognition: The drug has already been approved for sale in the UK.
·Market Potential: Targeting a population of 29 million traditional smokers and 17 million e-cigarette users in the United States.
According to a report by germanic7 on July 6th, Cytisinicline was submitted for approval on June 26th, with expectations that it could become the first non-nicotine smoking cessation drug approved by the FDA in 20 years.
Currently, more than two-thirds of American smokers express a desire to quit smoking. The FDA has only approved two non-nicotine smoking cessation medications for the market. Recently, pharmaceutical company Biotech Sciences Corporation submitted an application for Cytisinicline, also known as Zytisine. The FDA will review its effectiveness, safety, and tolerability based on two large placebo-controlled Phase III clinical trials.
Cytisinicline is a naturally occurring plant alkaloid that selectively binds to nicotine receptors in the brain, reducing smokers' cravings for nicotine and alleviating withdrawal symptoms. This medication has been widely used for smoking cessation in Eastern European countries for decades and received approval from the UK Medicines and Healthcare products Regulatory Agency in 2019.
A study published in the Journal of the American Medical Association Internal Medicine shows that Cytisinicline has a positive effect on adult smokers looking to quit, and can reduce nicotine cravings during a 6 to 12-week treatment period. The study also suggests that Cytisinicline is effective in helping individuals quit using e-cigarettes.
Cytisinicline, as a medication to reduce nicotine dependence, may also be beneficial for individuals looking to quit nicotine pouches, although this has not been specifically studied. The National Institute for Health and Care Excellence (NICE) in the UK previously advised including Cytisinicline as part of smoking cessation treatment within the national healthcare system.
At the same time, the American Institute for Clinical and Economic Review stated that they are conducting an evidence review to assess the clinical effectiveness of Cytisinicline combined with behavioral support and compare it to existing smoking cessation products.
Smoking is one of the leading causes of preventable deaths, involving various diseases such as cardiovascular diseases, various cancers, and lung diseases. In October 2024, the FDA and the National Institutes of Health held a public meeting aimed at developing new smoking cessation products to help individuals of all ages, particularly those in vulnerable populations, successfully quit smoking.
Experts point out that the lack of effectiveness of smoking cessation products has led to a 15% failure rate for those attempting to quit smoking in 2022. If Cytisinicline is approved for the U.S. market, it will provide an important option for those looking to quit smoking. Meanwhile, healthcare providers and public health departments still need to emphasize the importance of smoking cessation and prevention.
Since the 1960s, the United States has made significant progress in reducing the smoking rate. However, there are still approximately 29 million adults using cigarettes and around 17 million using e-cigarettes. During the Trump administration, the Department of Health and Human Services cut funding for smoking cessation programs, leading experts to warn that this could result in a rebound in smoking rates.
Editor’s Note：
Despite the existence of various smoking cessation and tobacco alternative products, such as novel tobacco, the success rate of quitting smoking is still not ideal. The submission of Cytisinicline for FDA approval serves as a reminder that quitting smoking requires more scientific support and concerted efforts from society, healthcare professionals, and policymakers.
Whether it can obtain FDA approval and the extent to which it can play a role in practical applications still needs further review and validation.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
